跳至主要内容
临床试验/NCT01445327
NCT01445327终止不适用

A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies

National Cancer Institute (NCI)1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2007年2月20日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
9
试验地点
1
主要终点
Number of Participants With Specific Tumor Markers in Stool, Urine, or Serum Detected Prior to Treatment and After Treatment

研究概览

简要总结

Background:

  • Gastrointestinal cancers are among the most commonly diagnosed cancers in the United States.
  • There are currently no tests to predict how patients with gastrointestinal cancers will respond to radiation therapy or which patients may develop side effects from treatment.
  • Studies on tumor cells in the stool, urine, or blood from patients may provide valuable information that can be used to develop tests to determine which patients may need more or less aggressive therapy.
  • Studies of other substances in the stool, urine, or blood from patients may provide valuable information that can be used to develop tests to determine which patients are likely to develop side effects from radiation treatments.

Objectives:

  • To collect blood, urine and stool specimens from patients with gastrointestinal cancers who will undergo radiation therapy.
  • To study hormone and protein changes in these blood, urine and stool specimens before, during and after radiation treatment in order to develop a way to predict how gastrointestinal cancers will respond to radiation therapy and if patients with these cancers will develop side effects from radiation treatment.

Eligibility:

-Patients 18 years of age and older with cancer of the gastrointestinal tract (esophagus, stomach, pancreas, rectum) who plan to receive radiotherapy to the site of the cancer on an National Cancer Institute (NCI) protocol

Design:

Participants undergo the following procedures:

  • Tumor biopsy: Before any treatment or at the time of surgery if it is the first treatment
  • Urine collection: Before, during, and after treatment and at follow-up visits.
  • Stool collection: Before, during, and after treatment and at follow-up visits.
  • Blood collection: Before, during, and after treatment and at follow-up visits.
  • Intestinal permeability assessment: Before any treatment, before radiation (if radiation is not the first treatment), 1 month after radiation is completed, and 3 months after radiation is completed. This test determines how the patients intestines are working to absorb sugar and may provide information about side effects from radiation treatments. Patients fast after midnight, then drink a small glass of sugars, and then do a 6-hour urine collection.

详细描述

Background:

  • Gastrointestinal (GI) carcinomas represent one of the most commonly diagnosed malignancies in the United States.
  • A sensitive and specific marker of tumor persistence or recurrence would permit a more accurate determination of the appropriateness of adjuvant therapy in patients with no clinical evidence of disease following curative resection and allow the diagnosis of recurrences at earlier stages that may be amenable to curative salvage therapies.
  • A biomarker detectable shortly after treatment or in the early stages of chronic radiation toxicity may allow the identification of patients at risk and early intervention.

Objectives:

  • Our primary objective is to determine if patient specific tumor markers in stool, urine, or serum can be reliably detected prior to treatment and followed after treatment to monitor the extent of residual disease.
  • A second objective is to evaluate the predictive value of potential markers of chronic gastrointestinal injury after radiotherapy.

Eligibility:

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of Participants With Specific Tumor Markers in Stool, Urine, or Serum Detected Prior to Treatment and After Treatment

时间窗: Prior to treatment (baseline) and after treatment, up to 19 months

Here are the number of participants with specific tumor markers in stool, urine, or serum detected prior to treatment and after treatment to monitor the extent of residual disease.

次要结局

  • Number of Participants With Chronic Gastrointestinal Injury After Radiotherapy(After radiotherapy, up to 19 months)

研究者

申办方类型
Nih
责任方
Principal Investigator
主要研究者

Deborah Citrin, M.D.

Principal Investigator

National Cancer Institute (NCI)

研究点 (1)

Loading locations...

相似试验

Predictors of Tumor Response and of Radiation... | 临床试验